Video

Q&A With Hayes Dansky From Janssen Pharmaceuticals: Using Xarelto to Treat Venous Thromboembolism In Everyday Practice

Author(s):

Venous thromboembolism is a serious condition that requires a high level of care and treatment. A recent study looked at how the prescribing of Xarelto has helped the treatment process.

Venous thromboembolism (VTE) is a serious condition that requires a high level of care and treatment. A recent study looked at how the prescribing of Xarelto has helped the treatment process.

Hayes Dansky, MD, from Janssen Pharmaceuticals discussed the condition which affects almost 900,000 people in America every year during the annual meeting of the American Society of Hematology in Orlando. Dansky's presentation focused on the Xalia study which looked at how the medicationw as was being used in real world patient care and how effective it was in helping this patient population.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.